EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic Targets for Lung Squamous Cell Carcinoma: Proteome‐Wide Mendelian Randomization and Potential Drug Prediction

Tao Xiang, Tingting Hu, Jiantong Sun iD, Qikun Geng, Jiazun Yang, Zhongyu Jian iD

The Clinical Respiratory Journal · 2026-03 · 20 (3)

DOI: 10.1111/crj.70182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Clinical Respiratory Journal, online erschienen am 17.03.2026. Verfasst von Tao Xiang und 5 weiteren Autor:innen. Beteiligte Einrichtung: West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Mendelian Randomization Analysis, Carcinoma, Squamous Cell, Proteome. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung squamous cell carcinoma (LUSC) is one of the most prevalent subtypes of lung cancer, accounting for approximately 25%. Mendelian randomization (MR) analysis of plasma proteins can identify potential drug targets for LUSC.

Methods

We obtained genetic instruments for plasma proteins from a GWAS by Sun BB et al. conducted on 3301 healthy adults. GWAS summary statistics of LUSC were from ILCCO. We conducted a two‐sample MR analysis to investigate the causal relationships between plasma proteins and the risk to LUSC. Colocalization analysis was used to test whether two traits share the same causal variables. Survival analysis based on potential proteins was conducted using transcriptomic data from TCGA database to determine whether gene expression levels are associated with the prognosis of LUSC patients. Moreover, predictions of potential drug ligands and molecular dockings were performed to evaluate the pharmaceutical properties of the target genes.

Results

Proteome‐wide MR analysis identified three proteins (MICB, SPINK2, TXNDC11) that showed a strong association with decreased risk of LUSC after FDR correction. Increased levels of MICB [OR(95% CI) = 0.72(0.63, 0.83); p = 3.90E−06], SPINK2 [OR (95% CI) = 0.74 (0.66, 0.84); p = 1.25E−06], TXNDC11 [OR (95% CI) = 0.63(0.51, 0.78); p = 2.69E−05] per SD decreased the risk of LUSC specifically. Sensitivity analysis revealed that there was no significant heterogeneity, pleiotropy, or reverse causality between these proteins and LUSC. Colocalization analysis indicated that three proteins shared the same variants with LUSC. Survival analysis showed that upregulation of SPINK2 was associated with a favorable prognosis in LUSC patients, while MICB and TXNDC11 were not. The expression of MICB, SPINK2, TXNDC11 was found to be potentially affected by specific substances, and our molecular docking showed a stable binding between SPINK2 and danazol, suggesting its potential as a drug target.

Conclusion

This study identified SPINK2 causally associated with the risk and prognosis of LUSC, which is a promising target for LUSC. The drug prediction we performed illustrated the medicinal potential of SPINK2, and the high binding activity of molecular docking indicated its strong potential as a drug target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsMendelian Randomization AnalysisCarcinoma, Squamous CellProteomeHumansGenome-Wide Association StudyPrognosisTrypsin Inhibitor, Kazal Pancreatic

Stichwörter der Autor:innen

Mendelian randomizationlung squamous carcinomaplasma proteinsurvival analysis

Substanzen

ProteomeTrypsin Inhibitor, Kazal Pancreatic

Autor:innen und Institutionen

  • West China Hospital, Sichuan University, Chengdu, China.
  • Institute of Thoracic Oncology and Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, China.

ORCID-Profile: Jiantong Sun, Zhongyu Jian

Zitieren

APA

Xiang, T., Hu, T., Sun, J., Geng, Q., Yang, J., & Jian, Z. (2026). Therapeutic Targets for Lung Squamous Cell Carcinoma: Proteome‐Wide Mendelian Randomization and Potential Drug Prediction. The Clinical Respiratory Journal, 20(3). https://doi.org/10.1111/crj.70182

Vancouver

Xiang T, Hu T, Sun J, Geng Q, Yang J, Jian Z. Therapeutic Targets for Lung Squamous Cell Carcinoma: Proteome‐Wide Mendelian Randomization and Potential Drug Prediction. The Clinical Respiratory Journal. 2026;20(3). doi:10.1111/crj.70182

BibTeX
@article{Xiang2026,
  author = {Xiang, Tao and Hu, Tingting and Sun, Jiantong and Geng, Qikun and Yang, Jiazun and Jian, Zhongyu},
  title = {Therapeutic Targets for Lung Squamous Cell Carcinoma: Proteome‐Wide Mendelian Randomization and Potential Drug Prediction},
  journal = {The Clinical Respiratory Journal},
  year = {2026},
  volume = {20},
  number = {3},
  doi = {10.1111/crj.70182}
}
Kostenlos starten →